|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
75,280,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
48,805 |
73,805 |
576,095 |
Total Sell Value |
$0 |
$2,098,369 |
$3,065,869 |
$22,449,223 |
Total People Sold |
0 |
4 |
5 |
10 |
Total Sell Transactions |
0 |
6 |
7 |
22 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Garofalo Elizabeth A. |
|
|
2024-03-08 |
4 |
S |
$45.69 |
$95,583 |
D/D |
(2,092) |
0 |
|
- |
|
Garofalo Elizabeth A. |
|
|
2024-03-08 |
4 |
D |
$46.16 |
$64,993 |
D/D |
(1,408) |
2,092 |
|
- |
|
Garofalo Elizabeth A. |
|
|
2024-03-08 |
4 |
OE |
$18.56 |
$64,960 |
D/D |
3,500 |
3,500 |
|
- |
|
Robin Sherrington |
EVP, Strategy & Innovation |
|
2024-03-07 |
4 |
S |
$46.15 |
$330,290 |
D/D |
(7,137) |
8,398 |
|
- |
|
Robin Sherrington |
EVP, Strategy & Innovation |
|
2024-03-07 |
4 |
D |
$45.96 |
$69,124 |
D/D |
(1,504) |
15,535 |
|
- |
|
Robin Sherrington |
EVP, Strategy & Innovation |
|
2024-03-07 |
4 |
OE |
$9.85 |
$85,114 |
D/D |
8,641 |
16,824 |
|
- |
|
Gannon Steven |
|
|
2024-03-07 |
4 |
S |
$46.20 |
$601,615 |
D/D |
(13,000) |
2,000 |
|
- |
|
Robin Sherrington |
EVP, Strategy & Innovation |
|
2023-12-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,398) |
8,398 |
|
- |
|
Azab Mohammad |
|
|
2023-12-19 |
4 |
OE |
$9.85 |
$42,552 |
D/D |
4,320 |
74,225 |
|
- |
|
Patou Gary |
|
|
2023-12-14 |
4/A |
S |
$41.05 |
$311,898 |
I/I |
(7,598) |
4,902 |
|
- |
|
Patou Gary |
|
|
2023-12-13 |
4 |
S |
$41.05 |
$311,898 |
I/I |
(7,598) |
4,902 |
|
- |
|
Patou Gary |
|
|
2023-12-13 |
4 |
S |
$38.94 |
$447,085 |
D/D |
(11,380) |
23,573 |
|
- |
|
Patou Gary |
|
|
2023-12-13 |
4 |
D |
$39.68 |
$119,913 |
D/D |
(3,022) |
27,550 |
|
- |
|
Patou Gary |
|
|
2023-12-13 |
4 |
OE |
$9.00 |
$137,487 |
D/D |
14,402 |
28,717 |
|
- |
|
Graham Dawn |
|
|
2023-08-24 |
4 |
S |
$38.70 |
$967,500 |
D/D |
(25,000) |
25,000 |
|
- |
|
Pimstone Simon N. |
|
|
2023-06-01 |
4 |
S |
$38.78 |
$1,231,247 |
D/D |
(31,713) |
6,000 |
|
- |
|
Pimstone Simon N. |
|
|
2023-06-01 |
4 |
D |
$38.53 |
$870,971 |
D/D |
(22,605) |
30,255 |
|
- |
|
Pimstone Simon N. |
|
|
2023-06-01 |
4 |
OE |
$7.69 |
$870,855 |
D/D |
54,318 |
51,000 |
|
- |
|
Pimstone Simon N. |
|
|
2023-05-31 |
4 |
S |
$38.53 |
$2,420,051 |
D/D |
(62,526) |
6,000 |
|
- |
|
Pimstone Simon N. |
|
|
2023-05-31 |
4 |
D |
$38.37 |
$1,124,586 |
D/D |
(29,309) |
32,856 |
|
- |
|
Pimstone Simon N. |
|
|
2023-05-31 |
4 |
OE |
$9.85 |
$1,181,875 |
D/D |
79,835 |
56,000 |
|
- |
|
Pimstone Simon N. |
|
|
2023-05-30 |
4 |
S |
$38.63 |
$1,453,672 |
D/D |
(37,006) |
18,000 |
|
- |
|
Mortimer Ian |
PRESIDENT & CEO |
|
2023-05-24 |
4 |
S |
$41.37 |
$1,310,931 |
D/D |
(31,655) |
31,302 |
|
- |
|
Mortimer Ian |
PRESIDENT & CEO |
|
2023-05-24 |
4 |
D |
$41.84 |
$518,105 |
D/D |
(12,383) |
32,709 |
|
- |
|
Mortimer Ian |
PRESIDENT & CEO |
|
2023-05-24 |
4 |
OE |
$9.44 |
$665,536 |
D/D |
69,340 |
33,880 |
|
- |
|
231 Records found
|
|
Page 1 of 10 |
|
|